Literature DB >> 26177314

Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.

Karen Gomez-Hernandez1, Shereen Ezzat, Sylvia L Asa, Özgür Mete.   

Abstract

Pituitary adenomas comprise a heterogenous group of adenohypophyseal tumours with distinct clinicopathological features across both the clinically functioning and silent groups. Although, predicting a clinically aggressive course remains challenging, accurate subtyping of pituitary adenomas offers valuable prognostic information that together with other clinical and radiological information serves as a platform for tailored treatment and follow-up. For instance, silent subtype 3 pituitary adenomas, silent corticotroph adenomas, acidophil stem cell adenomas, Crooke cell adenomas, and sparsely granulated somatotroph adenomas show more invasive growth. This review has been formulated as a set of practical questions that address the distinct clinical behaviour of a selected group of pituitary adenoma subtypes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26177314     DOI: 10.5146/tjpath.2015.01311

Source DB:  PubMed          Journal:  Turk Patoloji Derg        ISSN: 1018-5615


  12 in total

Review 1.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 2.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

3.  Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2021-04-17       Impact factor: 3.943

Review 4.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

Review 5.  Aggressive nonfunctioning pituitary neuroendocrine tumors.

Authors:  Sérgio Portovedo; Leonardo Vieira Neto; Christina Maeda Takiya; Leandro Miranda-Alves; Paula Soares; Denise Pires de Carvalho
Journal:  Brain Tumor Pathol       Date:  2022-06-20       Impact factor: 3.154

6.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Authors:  Ozgur Mete; Karen Gomez-Hernandez; Walter Kucharczyk; Rowena Ridout; Gelareh Zadeh; Fred Gentili; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

Review 7.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

8.  Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas.

Authors:  Laura Sanchez-Tejada; Ruth Sanchez-Ortiga; Cristina Lamas; Rosa Camara; Pedro Riesgo; Carmen Fajardo; Francisco Ignacio Aranda; Antonio Pico
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

Review 9.  Clinical and Pathological Aspects of Silent Pituitary Adenomas.

Authors:  Juliana Drummond; Federico Roncaroli; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

10.  Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology.

Authors:  Filip Garbicz; Dawid Mehlich; Beata Rak; Emir Sajjad; Maria Maksymowicz; Wiktor Paskal; Grzegorz Zieliński; Paweł K Włodarski
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.